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Emma R Miller1*, Stephen McNally2, Jack Wallace2 and Marisa Schlichthorst3Abstract
Background: Many countries have developed, or are developing, national strategies aimed at reducing the harms
associated with hepatitis C infection. Making these strategies relevant to the vast majority of those affected by
hepatitis C requires a more complete understanding of the short and longer term impacts of infection. We used a
systematic approach to scope the literature to determine what is currently known about the health and
psychosocial impacts of hepatitis C along the trajectory from exposure to ongoing chronic infection, and to identify
what knowledge gaps remain.
Methods: PubMed, Current Contents and PsychINFO databases were searched for primary studies published in the
ten years from 2000–2009 inclusive. Two searches were conducted for studies on hepatitis C in adult persons
focusing on: outcomes over time (primarily cohort and other prospective designs); and the personal and
psychosocial impacts of chronic infection. All retrieved studies were assessed for eligibility according to specific
inclusion/exclusion criteria, data completeness and methodological coherence. Outcomes reported in 264 included
studies were summarized, tabulated and synthesized.
Results: Injecting drug use (IDU) was a major risk for transmission with seroconversion occurring relatively early in
injecting careers. Persistent hepatitis C viraemia, increasing age and excessive alcohol consumption independently
predicted disease progression. While interferon based therapies reduced quality of life during treatment,
improvements on baseline quality of life was achieved post treatment – particularly when sustained viral response
was achieved. Much of the negative social impact of chronic infection was due to the association of infection with
IDU and inflated assessments of transmission risks. Perceived discrimination was commonly reported in health care
settings, potentially impeding health care access. Perceptions of stigma and experiences of discrimination also had
direct negative impacts on wellbeing and social functioning.
Conclusions: Hepatitis C and its management continue to have profound and ongoing impacts on health and
social well being. Biomedical studies provided prospective information on clinical aspects of infection, while the
broader social and psychological studies presented comprehensive information on seminal experiences (such as
diagnosis and disclosure). Increasing the focus on combined methodological approaches could enhance
understanding about the health and social impacts of hepatitis C along the life course.
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Hepatitis C infection is now acknowledged as an issue of
major public health importance for most countries in
the world [1]. In Australia, hepatitis C is one of the most
commonly notified communicable diseases with an esti-
mated prevalence approaching 1.5% [2]. Nationally, there
have been over 230,000 notifications since 1995 (when
mandatory notification was established in all jurisdic-
tions) and the annual number of new notifications has
averaged around 12,000 for the past five years [3]. Re-
cent estimates put the global hepatitis C prevalence at
around 2.4%, with up to 170 million people now thought
to be chronically infected [4]. Between 70% and 85% of
those initially infected fail to clear the virus [5-7]. Hepa-
titis C treatments are available, but uptake remains low
even in countries such as Australia, where treatment is
available at low cost to eligible patients [8,9]. Thus, most
people with hepatitis C infection face the prospect of
lifelong chronic infection.
The personal impacts of a diagnosis of hepatitis C in-
fection are known to be significant. The direct effects of
the virus and its management on wellbeing can lead to
people making significant lifestyle changes including re-
ducing work hours or alcohol consumption [10,11],
which may in turn influence economic status and social
participation. There can be negative social implications
for people living within the context of a broader com-
munity who may be largely uneducated about hepatitis
C transmission. In most cultures around the world there
is prevailing marginalization of people who inject drugs
– the major risk factor for infection [12-14]. Disclosure
of hepatitis C status can result in alienation from family
and friends as well as perceived and actual discrimin-
ation in health services and workplaces [12]. As with
other chronic diseases, experiences of diagnosis and
management are shaped by a multitude of physical and
psychosocial forces. Such forces influence the dynamics
of adaptation to illness and impact on well being, often
without direct linearity, over time [15]. Given the size of
the affected population, having an understanding of
these forces in relation to adapting to, and living with,
hepatitis C is critical for effective health policy planning.
Many countries have developed, or are currently devel-
oping, national strategies aimed at reducing the harms
associated with hepatitis C. For example, the soon to be
released National Liver Strategy represents the second
strategy for the United Kingdom, while the Third National
Hepatitis C Strategy (covering the period 2010 to 2013)
has now been implemented in Australia. Making these
strategies relevant to the vast majority of those affected by
hepatitis C, particularly those for whom treatment does
not appear to be either useful or desirable, would seem to
require a greater understanding of the ongoing impacts of
hepatitis C diagnoses. Using a systematic approach, weundertook a scoping exercise of the biomedical and social
literature published in the ten years from 2000 on the on-
going health and social consequences of diagnoses with
hepatitis C infection. We searched for studies on hepatitis
C in adult persons in which the health or social outcomes
of infection were investigated (including studies of hepa-
titis C transmission). We specifically searched for cohort
studies (and other longitudinal designs) as well as studies
using qualitative methodologies. The objective of this
study was to determine what is currently known about the
health and social impacts of hepatitis C along the trajec-
tory from exposure to ongoing chronic infection, and to
identify what knowledge gaps remain.
Methods
We developed an inclusive search strategy aimed at in-
cluding studies using both qualitative and quantitative
approaches. We searched the health literature in the
PubMed (incorporating Medline), Current Contents and
PsychINFO data bases for the years 2000 to 2009 inclu-
sive, using two different strategies. The first search used
the terms “(hepatitis C OR HCV) AND (cohort study OR
follow up study OR longitudinal study OR prospective
study OR retrospective study OR concurrent study)”; and
the second search used the terms “(hepatitis C OR HCV)
AND (quality of life OR social impact OR socioeconomic
impact OR psychological well being).” We limited the
search to primary studies in adults and excluded investi-
gations that focused solely on evaluating the performance
of diagnostic tools and experimental interventions with-
out providing retrievable data on patient health outcome
beyond biochemical or serological endpoints (Table 1).
To enhance the relevance of reviewed studies to the
current context of hepatitis C and its management, we
excluded studies published before January 2000, limited
to the end of the last full calendar year at the time of the
review – December 2009. Resource and time restrictions
limited the search to English language journal publica-
tions. Studies were excluded if specific data on hepatitis
C outcomes were not retrievable (for example, in a study
of liver disease in general). We also excluded studies that
solely focused on quantifying hepatitis C treatment side
effects, unless the personal impact of the symptoms was
also investigated – for instance, their effect on quality of
life, social function or reported health status. The spe-
cific inclusion and exclusion criteria were as follows:
Inclusion criteria
 Primary studies
 Adult participants
 Hepatitis C specific data provided
 Publication between January 1, 2000 and December
31, 2009
 English language
Table 1 Example of electronic search strategies used – limits: Humans, Male, Female, English, All Adult: 19+ years,
Publication Date from 2000/01/01 to 2009/12/31
Search strategy 1 Search strategy 2
Search terms: “(hepatitis C OR HCV) AND (cohort study OR
follow up study OR longitudinal study OR
prospective study OR retrospective study
OR concurrent study)”
“(hepatitis C OR HCV) AND (quality
of life OR social impact OR
socioeconomic impact OR
psychological well being).”
Number of studies
identified in total:
1608 335
Number of studies
excluding reviews:
1592 320
Number of studies
excluding experimental trials
570 299
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 Data not provided on participant health outcome
(beyond serologic endpoints)
 Relevant outcome data not retrievable
 Non-English language
 Previously published analyses of the same data
All identified abstracts were scanned, before relevant
articles were retrieved and reviewed. When the same co-
hort was described in successive publications, only the
latest publication was reviewed except where subsequent
analyses focused on different outcomes. The reference
lists of reviewed articles were also scrutinized for any
additional items relevant to the review. Records of all
articles retrieved were stored and managed in EndNote
(version X3.0.1).
As this review aimed to determine if it was possible to
build a picture of the trajectory of a hepatitis C diagnosis
by summarizing the evidence from a broad range of eli-
gible studies (using both quantitative and qualitative
approaches), the quality assessment was restricted to the
completeness of information provided by the authors.
Studies were required to provide sufficient data to
characterize the participants (e.g. by age, sex, and popula-
tion group), the follow up period (if relevant to the design),
the methodological approach (including any instruments
utilized), and outcomes (including appropriate measures
of effect such as Relative Risk and Hazard Ratios, in the
case of quantitative designs). Inclusion and exclusion cri-
teria were developed by consensus of the authors as were
the categories assigned to the reviewed studies. Eligible
studies were then summarized and reviewed by the re-
search team, before coding into the specified categories for
narrative synthesis. See Additional file 1 for the full list of
included articles, as well as their tabulated summaries.
Results
We identified 140 cohort (or follow up) studies with our
first strategy (see Figure 1) and 133 studies with oursecond strategy. With the exception of eight studies (all
of which investigated health related quality of life), there
was little duplication between the results obtained using
the two sets of search terms.
Temporal experience of hepatitis C
The cohort studies provided comprehensive information
on the clinical and epidemiological impacts of hepatitis
C over time and covered the broad categories of: trans-
mission; natural history; health related quality of life
during the course of antiviral treatment; and health out-
comes after antiviral treatment or liver transplant (see
Table 2). With the exception of eight studies in people
undergoing antiviral treatment, no cohort studies inves-
tigated the personal or social experiences, of living with
hepatitis C.
Transmission of Hepatitis C
We identified 42 cohort studies investigating the trans-
mission of hepatitis C in various community and hos-
pital based populations. Eighteen of these followed up
community-based injecting drug users (IDU) and
two studies also included non-injecting participants
(see Additional file 1: Table S1). In thirteen, the IDU
cohort was seronegative for hepatitis C at baseline, with
rates of new infection ranging from 8.1 to 45.8 per 100
person-years. While all reported incidence rates were
significantly higher than in non-IDU, rates appeared to
be unrelated to the period of follow up. This may be due
to infection of susceptible populations relatively early in
their injecting careers. Roy et al. [16] noted that around
50% of a cohort of IDU in Canada had seroconvert
within the first four years of injecting, and Maher et al.
[17] found that being within the first year of injecting in-
dependently predicted hepatitis C seroconversion after
adjusting for a range of demographic factors and risk
behaviours. Re-infection rates among IDU previously
achieving viral clearance tended to be lower than
new infection rates – suggesting a role for host re-
lated factors.
Figure 1 Flow chart of included and excluded studies identified in search strategy 1.
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the general population and its subpopulations (see
Additional file 1: Table S2). Studies undertaken in
general population samples in Chile, Italy and Japan in-
dicate tha the incidence of hepatitis C general populations
overall was low compared to IDU populations – rangingTable 2 Identified hepatitis C follow-up studies published in 2
*Category (number
of studies)
Country of study (number of studies) Population
Transmission (42) Australia (5); Brazil (1); Canada (5);
Chile (1); China (2); Denmark (1);
Egypt (3); Germany (1); Italy (3);
Japan (3); Netherlands (1); Scotland
(1); Spain (1); Switzerland (1);
Thailand (1); UK (3); US (9)
Endoscopy
hemodialys
(18); men w
with HIV (3)
Natural history (69) Australia (2); Canada (1); China (1);
Denmark (2); Europe – 8 centres (2);
France (1); Greece (1); Ireland (1);
Italy (9); Japan (19); Netherlands (2);
Spain (6); Sweden (3); Switzerland (1);
Thailand (1); Turkey (1); Taiwan (2);
UK (2); US (12)
Hepatitis C
morbidity (4
or cf. Mono
C and HIV c
outcomes (
or cf. mono
Antiviral treatment
related quality of
life (8)
Italy (1); Sweden (1); Turkey (1); US (5) Patients un
assessed pr
Health outcomes
post treatment or
other management
(28)
Canada (4); Europe – 8 centres (1);
France (1); Greece (1); Italy (2); Japan
(7); Norway (1); Switzerland (2);
Thailand (1); US (8)
Hepatitis C
treatment (
HIV co-infec
response (4
with/out he
*seven studies are included in more than one category.from 0.01 to 0.4 per 100 person years in four identified
studies. A higher general population rate was reported by
Grebely et al. [18] – 7.4 per 100 person years – who
sampled an inner city population that included a high pro-
portion of IDU. Reported rates were higher in renal
patients undergoing long term hemodialysis in some000 to 2009 – n=140
s or study focus (number of studies) Follow up
period range
Sample size
range
patients (1); general populations (5);
is patients (5); injecting drug users
ho have sex with men (2); people
; perinatal populations (4); prisoners (4)
0.3 to 11 years 18 to 6,412
mono-infection, with/out co
1); hepatitis B and C co-infection,
-infection outcomes (15); hepatitis
o-infection, or cf. Mono-infection
11); hepatitis C, B and HIV co-infection,
–infection outcomes (2);
1.0 to 35 years 17 to 474,369
dergoing treatment (4); patients
e- and post-treatment (4)
Up to 1.4 years 18 to 1,144
mono-infection and antiviral
15); hepatitis C, hepatitis B and/or
tion – hepatitis C antiviral treatment
); post liver transplant patients,
patitis C antiviral treatment (9)
0.5 to14.4 years 45 to 13,855
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Germany in line with improving infection control
practices.
There is evidence that perinatal transmission is asso-
ciated with maternal hepatitis C viraemia, and is signifi-
cantly more frequent in maternal HIV co-infection.
While up to 31 percent of babies born to mothers with
hepatitis C were reported to be seropositive shortly after
birth, Sbebl et al. [19] found that only 2.4% remain so by
three years of age. Hepatitis C transmission in people
already infected with HIV, and in HIV negative men
who have sex with men, was relatively low – and oc-
curred mainly through injecting drug use. Four studies
in the UK and Australia demonstrated an elevated trans-
mission rate in prisoner populations – particularly in
prisoners reporting injection drug use whilst incarcer-
ated. Dolan et al. [20] estimated a rate of 21.3 per 100
person years in imprisoned heroin users, while a rate of
4.6 per 100 person years was observed in the South Aus-
tralian prison population [21] – although community ex-
posure couldn’t be ruled out in the latter study.
Natural history of chronic hepatitis C infection
We identified 69 cohort studies investigating the natural
history of chronic hepatitis C infection (see Additional
file 1: Table S3). Of these, 42 studies focused on health
outcomes for people mono-infected with hepatitis C,
while the remainder (27 studies) compared outcomes in
hepatitis C, hepatitis B or HIV mono- and co-infection.
Mortality, disease progression and development of hepa-
tocellular carcinoma (HCC) were outcomes investigated
by the majority of all studies, and a small number fo-
cused on viral clearance. Two studies investigated behav-
ioral outcomes – one looking at clinical factors
associated with treatment uptake and the other looking
at general practitioner (GP) patterns of management and
referral to specialists in hepatitis C.
The studies in people with untreated chronic hepatitis
C monoinfection had follow up periods ranging from
one to 35 years in samples of clinical groups as small as
17 to sample sizes approaching half a million from large
clinical data bases. The evidence for fibrotic changes and
development of liver cirrhosis, development of HCC and
increased liver-specific mortality in chronic hepatitis C
over time was relatively consistent. Several studies found
that the more serious complications of chronic infection
were predicted by the presence of persistent viraemia,
moderate to high alcohol consumption and increasing
age. Age was not as important in a study in elderly Ita-
lians with chronic hepatitis C, which found deaths to
non-liver related causes occurred more frequently than
liver-specific deaths over ten years of follow up. Studies
investigating health outcomes for people with persist-
ently normal alanine amino transferase (ALT) levelssuggest that liver cirrhosis and HCC do occur, but the
frequency and rate of disease progression tends to be
low relative to those with consistently high ALT levels.
Despite the apparent importance of this indicator, Yawn
et al. [22] found that less than half of primary care physi-
cians monitored ALT in their patients with hepatitis C.
While unlikely to have direct impact on the experience
of living with hepatitis C, a lack of ongoing ALT moni-
toring might eventually have implications for health out-
come in their patients. Yawn et al. also found there was
only limited and inconsistent management and referral
with respect to potential accelerators of progression such
as excessive alcohol consumption and viral co-infections.
Twenty seven studies compared the longer term
effects of chronic mono-infection with hepatitis C and
hepatitis B or HIV, and/or the impact of co-infection
with any of these. Fifteen studies investigated the inde-
pendent or combined effects of hepatitis B and C for be-
tween 3.4 and 23 years of follow up. While studies
varied in the order of risk for hepatitis B or C monoin-
fection, co-infection was relatively consistently asso-
ciated with greater incidence of HCC and lower survival
than mono-infection. In their 23 year follow up study,
Zampino et al. [23] found that earlier age at infection
was associated with a lower disease progression in both
mono- and co-infected patients.
Eleven studies were in cohorts infected with either
HIV or hepatitis C or both. Most of these compared the
independent effects of infection with each virus – with
outcomes such as AIDS, liver cirrhosis, and overall and
specific mortality. An exception was Grebely et al. [24]
who investigated hepatitis C viral clearance (rather than
disease outcome) in a community sample in Canada,
and found that co-infection with HIV and continuing
injecting drug use were associated with hepatitis C viral
persistence. In other studies, HIV-hepatitis C co-
infection was found to have a synergistic effect in which
the progression to AIDS and end stage liver disease and
liver-related death (mostly due to HCC) was accelerated.
Improvements in survival were calculated for HIV
patients in hepatitis C-related end stage liver disease
under active anti-retroviral treatment (HAART), al-
though this finding was not supported by other studies
in this group (see García-Garcia et al. [25] for example).
In their study of antiviral treatment initiation for hepa-
titis C in Denmark, Hansen et al. [26] found that 33% of
patients commenced treatment within five years and this
was predicted by higher ALT, HCV genotype 2 or 3 (the
most favourable for successful treatment outcome) and
HIV negative status.
We identified two cohort studies investigating the
combined and/or independent effects of infection with
hepatitis B, hepatitis C and HIV. Bonacini et al. [27]
found liver-related mortality in HIV patients was
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were co-infected, and was more common when both
were present. In a cohort of haemophilia patients with
HIV infection, Melendez-Morales et al. [28] found an
11-fold increase in hepatitis C viral clearance in the
presence of hepatitis B. The authors suggest that this
may be due to ‘mutual interference in viral replications’
– as is thought to occur in the presence of hepatitis D.
Health related quality of life during the course of antiviral
treatment
Eight cohort studies investigated the impact of hepatitis
C treatment on health related quality of life (QoL) (see
Additional file 1: Table S4). Six of these studies used the
36-item Medical Outcomes Study Short-Form 36
(SF-36) or the 12 item version (SF-12), in wide use
around the world to measure health status across eight
domains relevant to physical, mental and emotional
health. The SF-36 and various measures to establish de-
pression levels and other social and emotional dimen-
sions, uniformly demonstrated reduced health related
quality of life during treatment but improving post treat-
ment – particularly when sustained viral responses were
achieved. Evon et al. [29] found the prevalence of de-
pression was relatively high in patients prior to treat-
ment (12%) and this predicted early exit from treatment.
Depression newly diagnosed during treatment had a
lesser impact on early exit.
Health outcomes after antiviral treatment or liver
transplant
Twenty eight studies investigated health outcomes
following interferon based treatments (generally in
combination with Ribavirin) or after liver transplant
(see Additional file 1: Table S5). Fifteen studies were in
patients with no viral co-infection who were followed up
from six months to 14 years after treatment. In most
populations, sustained viral responses were attained in
between 20% and up to 80% depending on the viral
genotype (with genotypes other than 1 and 4 considered
the most favourable), and sustained viral responses were
associated with a lower incidence of complications such
as HCC and lower mortality. Dalgard et al. [30] demon-
strated that the comparable outcomes were achievable in
people who inject drugs, despite ongoing concerns about
compliance with treatment schedules and ongoing drug
use.
Four studies investigated treatment-related outcomes
in hepatitis C patients co-infected with either hepatitis B
or HIV. Ikeda et al. [31] found that any viral response to
hepatitis C treatment (transient or sustained) was pro-
tective for the development of HCC, but not in the case
of co-infection with hepatitis B. Co-infection with HIV
appeared to be a barrier to evaluation for, and uptake of,hepatitis C treatment although sustained response rates
(per genotype) have been reported to be similar to those
seen in hepatitis C mono-infection. Furthermore, hepa-
titis C disease progression may be slowed with treatment
even when sustained response is not achieved.
We identified nine cohort studies investigating health
outcomes after liver transplantation. Four of these studies
compared health outcomes in organ recipients with and
without markers for hepatitis C. In all cases, hepatitis C
was associated with lower survival and reduced overall
health and function. In their seven-year retrospective
study of patients following hepatitis C related liver trans-
plants, Gallegos-Orozco et al. [32] estimated a median
survival time of 3.5 years. According to Bizollon et al., [33]
sustained response to hepatitis C treatments provided
post-transplantation is associated with improved graft sur-
vival although not necessarily with improved survival.
The personal and psychosocial impacts of hepatitis C
Our second strategy identified 133 studies investigating
the personal experience and social impacts of hepatitis C
– in terms of individual wellbeing and psychosocial func-
tion (see Figure 2). The studies could be grouped into four
broad categories: two categories focusing on either the
QoL impacts of ongoing infection or its treatment; one
category exploring the psychosocial experience of living
with hepatitis C; and a final category focusing on experi-
ences of diagnosis and management of hepatitis C
(see Table 3). Most of the QoL studies used a quantitative
approach, while qualitative approaches were more com-
monly taken in the broader social research. Very few stud-
ies were longitudinal in design, with the majority focusing
on analyzing data collected at a single point in time.
Quality of life in untreated hepatitis C
Sixty six studies investigated quality of life (QoL), in-
cluding eight cohort studies in people undergoing treat-
ment also identified in the biomedical literature. Forty
five of these studies measured QoL impacts in untreated
chronic infection in community-based and clinic popula-
tions, former or current IDU, people with viral co-infec-
tions, patients with various stages of disease progression,
and patients with co morbidities (see Additional file 1:
Table S6). Again, the SF-36 (or SF-12) was the main in-
strument used to assess health related QoL, and several
studies used other validated instruments measuring
mental health and psychosocial status. The studies pro-
vide relatively consistent evidence of reduced QoL in un-
treated hepatitis C in most populations. The exception
was provided by Bailey et al., [34] who observed moder-
ate to high levels of QoL in US hepatitis patients, upon
whom the main negative impact was uncertainty sur-
rounding prognosis. In Australia, Thein et al. [35] found
little difference in QoL between HIV and hepatic C
Figure 2 Flow chart of included and excluded studies identified in search strategy 2.
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although the authors pointed out the numbers in each
group may have been too small to demonstrate clear
differences.
There was substantial variation among studies about
the relative impact of a range of co-factors on QoL. Sev-
eral studies concluded reduced QoL in hepatitis C was
independent of disease activity, liver histology and drug
and alcohol use. Gunasekera et al., [36] however, found
that QoL was reduced in hepatitis C patients recruited
from rural drug and alcohol services when compared to
rural primary care or hepatitis C centres. Continued
drug use was associated with reduced QoL in two other
studies, but not in others analyzing the role of substance
use. Two studies led by Kramer [37,38] both found
reduced QoL in hepatitis C which was associated with
fatigue, but not with observed slight neuro-cognitive im-
pairment. Fatigue and depression accounted for the ma-
jority of reduced QoL in a study of HIV-hepatitis C
coinfected patients in France [39].
Several studies proposed an emotional or psychosocial
basis for reduced QoL. Dalgard et al. [40] and Shwarzin-
ger et al. [41], for example, found that awareness of
hepatitis status explained much of the reduction in QoL.
Depression and psychiatric co morbidities were found to
be important in some studies, although others found
that the co-existence of mental illness failed to fully ex-
plain the QoL differentials in those with and without
hepatitis C. While several studies found little association
between QoL and ALT or liver fibrosis in clinic popula-
tions, advanced liver disease did appear to be closely
correlated with reduced QoL in hepatitis C.Quality of life related to hepatitis C treatment
Twenty two studies investigated health related QoL in
patients undergoing antiviral treatment or liver trans-
plantation, with the majority using the SF-36 (see
Additional file 1: Table S7). The studies were mainly
cross-sectional, with seven utilizing a follow up design (as
previously described). Most of the eleven studies in patients
undergoing interferon-based antiviral treatment noted
further reductions in health related QoL during the
treatment, with depression playing a significant role.
Improvements were noted post treatment in most stud-
ies, particularly where sustained virological clearance
was achieved. Fontana et al. [42] compared QoL in
patients who were accessing treatment and those who
were not. They found that emotional distress, which was
strongly associated with reduced QoL, was highest in
the untreated group – particularly in those who were an-
ticipating a fatal outcome to their chronic hepatitis C in-
fection. One study found no difference in QoL between
treated and untreated groups but did find that concur-
rent treatment had a negative impact on cognitive abil-
ities [43]. Studies of patients post treatment suggest that
the benefits of successful treatment can be sustained
over time, as can the deleterious effects of less successful
treatment. In their study of untreated patients, patients
who had relapsed after treatment and patients who did
not respond to treatment, Taliani et al. [44] found that
non-responders had the lowest QoL. Low quality of
life scores were independently associated with co mor-
bidity and non-response to treatment. They suggest
that treatment expectations may be important modifiers
of QoL.
Table 3 Identified hepatitis C social research studies published in 2000 to 2009 – n=133
*Category (number of studies) Country of study
(number of studies)
Populations or study focus
(number of studies)
Approach used (number of studies)
Quality of life in people with
untreated hepatitis C (45)
Australia (6); Austria (2) Brazil (2);
Canada (4); Egypt (1); France (1);
Germany (3); Ireland (2); Italy (2);
Mexico (1); Netherlands (1);
Norway (2); Serbia (1); Spain (1);
Sweden (1); Switzerland (1);
Taiwan (1); Turkey (3); US (10)
Community and clinic populations
(26); injecting drug users (2);
hepatitis B and/or HIV co-infection
(7); people with various stages of
disease progression (4); people
with comorbid conditions (3)
Quantitative approaches using surveys
incorporating physical and mental
health status instruments such as the
SF-36 or 12, Beck Depression
Inventory (45)
Quality of life in people during
or after antiviral treatment/
transplant for hepatitis C (22)
Australia (1); Canada (1); Germany (1);
Italy (3); Sweden (1); Taiwan (3);
Turkey (2); UK(1); US (9)
During antiviral treatment (13);
after antiviral treatment (5); after
liver transplantation (3)
Quantitative approaches using surveys
incorporating physical and mental
health status instruments such as the
SF-36 or 12, Beck Depression
Inventory (20)
Qualitative approaches involving
semi-structured or in-depth
interviews (2)
Psychosocial experience of
living with hepatitis C (43)
Australia (6); Canada (5); France (21);
Germany (2); Ireland (1); Italy (1);
Scotland (1); Turkey (1); UK (2); US (6)
Social functioning (6); life style
(6); general health and
well-being (9);
Quantitative approaches using surveys
incorporating clinical and psychosocial
data (26)
Qualitative approaches involving
semi-structured and/or in-depth
interviews, focus groups and
ethnographic observation (14) Mixed
methods using semi-structured
interviews and survey techniques (3)
Experience of diagnosis and
management of hepatitis C (26)
Australia (9); Australia & New
Zealand (1); Canada (3); France (1);
Ireland (5); Japan (1); New Zealand
(1); Pakistan (1); Turkey (1); UK (3);
US (15)
Diagnosis impact (6); stigma &
discrimination (5); health service
access (10); treatment decisions (5)
Quantitative approaches using surveys
incorporating clinical and psychosocial
data (11)
Qualitative approaches involving
semi-structured and/or in-depth
interviews, focus groups or daily
participant recordings (13)
Mixed methods using semi-structured
interviews and survey techniques (2)
*three studies are included in more than one category.
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related liver transplantation. Two quantitative studies
found significant impairments in QoL in recurrent hepa-
titis C (occurring in 36% to 62% of the study popula-
tions) in the years following transplants, while non-
recurrence was associated with improved functional per-
formance and quality of life over time. In a qualitative
study involving in-depth interviews with eight post
transplant patients, Dudley et al. [45] concluded that
stigma and disease uncertainty in hepatitis C continues
after liver transplants and may further impact adversely
on QoL in hepatitis C patients.
Psychosocial experience of living with hepatitis C infection
We identified 43 studies investigating the impact of
hepatitis C on social functioning, lifestyle, health and
well-being (see Additional file 1: Table S8). In a majority
of studies, diagnosis with hepatitis C was reported to
have profound impacts on social functioning. The per-
ceived stigma associated with infection led to high levelsof anxiety, and exaggerated fears of transmission and was
the main driver of social isolation and reduced intimacy
in relationships [46-48]. Grundy and Beeching [46] found
that fear of transmission – particularly in intimate rela-
tionships, child birth and child rearing – led to concerns
about being able to fulfil gender roles in a group of
women with hepatitis C. There is further evidence that
the social experience of living with hepatitis C differs be-
tween women and men. For instance, Temple-Smith
et al. [49] found substantial gender differences in health
seeking behaviours and notions of social support.
Fear of transmission, where the perceived risk is often
unnecessarily inflated, also appeared to result in un-
necessary changes in everyday practices, such as refrain-
ing from sharing towels and drinking glasses or not
taking part in food preparation [50]. Changes in intimate
and/or sexual practices, sometimes exhibiting as sexual
dysfunction, have been observed in association with de-
pression and anxiety about transmission [51]. Other life-
style impacts of hepatitis C include reductions in alcohol
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dietary intake [52]. In the context of competing priorities
including housing, employment and legal implications of
injecting, hepatitis C was viewed to be of less conse-
quence by some study participants who injected drugs,
but modification of risk behaviours (such as cleaning of
syringes and spoons, and less sharing of injecting para-
phernalia) was reported [53,54].
Infection with hepatitis C has been found by a number
of studies to have substantial impacts on health and well-
being, often in relation to fear and uncertainty about prog-
nosis [55]. One study found that feelings of hopelessness
in conjunction with uncertainty were experienced by
people with either hepatitis C or HIV, but tended to be
heightened in hepatitis C [56]. Perceived stigma and dis-
crimination impeded adaptation to the hepatitis diagnosis
and was a common source of anxiety in people with
chronic hepatitis C [56,57]. Hopwood and Treloar [58]
found that the psychosocial stress associated with hepatitis
C was less in those with a history of IDU, which may arise
from greater resilience in coping with hepatitis C stem-
ming from experiences of marginalization for people who
inject drugs. A number of studies investigated specific
symptoms of hepatitis C infection – with fatigue being the
most common, followed by depression and other mental
health issues. Bodily pain, particularly in the form of myal-
gia and a degree of cognitive impairment was also identi-
fied by several authors. The majority of studies found
symptoms were independent of disease activity or disease
severity, but associated with depression, anxiety and other
psychosocial factors. The direction of causation might
prove difficult to untangle, particularly where specific
symptoms are tightly clustered. Golden et al., [59] for in-
stance found that mood disorders were highly prevalent in
hepatitis C, and depression was associated with experi-
ences of illness – including stigma, poor adjustment to the
diagnosis and physical symptoms. There were three stud-
ies that suggested a biological cause for a slight cognitive
impairment observed in hepatitis C [60-62].
Responses to diagnosis and management of hepatitis C
Finally, we identified 26 studies investigating experiences
related to diagnosis and treatment (see Additional file 1:
Table S9). With some degree of overlap, these studies fo-
cused on the immediate impact of diagnosis and percep-
tions of stigma and discrimination in relation to it,
accessing health services and making decisions about
treatment. Diagnosis with hepatitis C could be a stressful
event, characterized by feelings of shock and devastation
that transitioned into enduring emotional, psychosocial
and even physical effects [63]. For some, the time of
diagnosis was an event equivalent to the stress of events
such as moving cities, losing a job, marital breakdown
and divorce [64]. Some studies, however, described amore dynamic response that was mediated by changes
in social context [65]. For instance, the threat of HIV
and issues related to substance use was considered a
higher priority in some groups [66].
The perception of stigma is generally an internalized
phenomenon resulting from individually held under-
standings and interpretations, or arising in response to
actual or perceived discrimination. For instance, study
participants described perceptions of stigma resulting
from feelings of contamination and fear of disclosure to
others, from whom they anticipated rejection, much of
which was on the basis of fear of disease transmission
[67]. Golden et al. [68] found perceived stigma was asso-
ciated with decreased acceptance of illness, decreased
social adjustment and increased reported symptoms in
hepatitis C.
Discrimination can flow from the beliefs and attitudes
of others and ultimately shape perceptions of stigma
through the differential treatment of people with par-
ticular conditions. As Paterson et al. [69] describe, how
illnesses are constructed by health providers influences
not only the care offered, but also feeds into the self per-
ception of the affected person. Many study participants
reporting negative experiences in health care settings in
relation to perceived discrimination. In one study of over
500 people with hepatitis C, 65% reported having experi-
enced health care discrimination, which was associated
with pessimism about future health and decreased social
interaction among other things [70]. Perceived discrim-
ination was also found to be a significant barrier to
health treatment access, to the extent that refusal of
treatment by providers was reported [71]. Harris [72]
found that reports of refusal or withdrawal of health care
were common and contributed to a reluctance to dis-
close to health professionals even in the context of a
perceived obligation to do so.
Five studies investigated treatment decision making,
confirming that concern about side effects remains an
important reason for declining or adhering to treatment.
McNally et al. [8] proposed that confidence in treatment
efficacy was the main consideration in deciding to
undertake treatment. Underscoring the contextual influ-
ences involved in making treatment decisions, Ogawa
and Bova [73] suggested that treatment decisions in
former IDU were complicated by fears that self injecting
interferon could reintroduce the use of syringes in a way
that might threaten their control over their injecting
drug use. Treloar and Hopwood [74] encountered what
they defined as ‘unrealistic optimism’ in both patients
and health care providers, in which the applicability of
information about possible side effects was underesti-
mated. This may have implications for delay in treat-
ment for mental health issues that might arise during
antiviral treatment (Table 4).
Table 4 Summary of findings from the biomedical and social literature on the ongoing clinical and psychosocial
impacts of diagnoses with hepatitis C infection
Category Findings
Transmission • Strongly associated with injection drug use – likely to occur early in injecting career.
• Maternal transmission associated with hepatitis C viraemia – more frequent in maternal
HIV co-infection.
• Prisoner populations at enhanced risk for infection.
Natural history • Chronic infection can progress to fibrotic changes and development of liver cirrhosis,
development of hepatocellular carcinoma (HCC) and increased liver-specific mortality
• Complications of chronic infection predicted by persistent viraemia, moderate to high
alcohol consumption and increasing age.
• Liver cirrhosis and HCC occur in persistently low serum alanine amino transaminase
(ALT), but frequency and rate of disease progression low relative to consistently high serum ALT.
• Hepatitis B co-infection associated with greater incidence of HCC and lower survival than
mono-infection with either virus.
• HIV-HCV co-infection found to accelerate progression to AIDS, end stage liver disease and
liver-related death (mostly due to HCC).
Health related quality of life (QoL) • Relatively consistent evidence of reduced QoL in untreated hepatitis C in most populations.
• Variation among studies about the relative impact of a range of co-factors on QoL, although
disease activity found to be independent of QoL.
• Interferon-based treatments associated with further reductions in health related QoL, with
depression playing a significant role.
• QoL improves post treatment – particularly if sustained viral responses achieved.
• QoL benefits of successful treatment can be sustained over time (possibly the deleterious effects).
Health outcomes after antiviral
treatment or liver transplant
• In most populations, including IDUs, sustained viral responses attained from 20% to 80%
depending on viral genotype (types other than 1 and 4 considered the most favourable).
• Sustained viral response associated with lower incidence of complications (e.g. HCC and death).
• Hepatitis C associated with lower survival and reduced overall health and function in organ
transplant patients.
Psychosocial experience of living
with hepatitis C infection
• Diagnosis with hepatitis C reported to have profound impacts on social function.
• Perceived stigma led to high levels of anxiety and over-inflated assessments of transmission risks.
• Fatigue the most common symptom reported, followed by depression and other mental
health issues, and myalgia.
• Symptoms independent of disease activity or disease severity, but reported to be associated
with depression, anxiety and other psychosocial factors with some biological mechanisms proposed.
Responses to diagnosis and
management of hepatitis C
• Diagnosis with hepatitis C often reported to be a stressful event, potentially mediated by
personal and social context.
• Perceived discrimination reported in multiple settings, including in interactions with health
care services.
• Potentially a barrier to health service access and treatment
• Fear of side effects reported as a major influence on treatment decisions.
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In this paper we reviewed the biomedical and social lit-
erature on the ongoing clinical and psychosocial impacts
of diagnoses with hepatitis C infection. The published lit-
erature provides useful information on selected aspects
of living with hepatitis C. Identified cohort studies pro-
vided prospective information on clinical aspects of
chronic infection in the longer term, with some studies
involving very large numbers of patients who were fol-
lowed up for considerable lengths of time. The social re-
search presented in depth information on some of thesocial and personal ramifications of living with hepatitis
C in the form of comprehensive and contextual ‘snap-
shots’ of seminal experiences, such as diagnosis and dis-
closure to others. Yet questions still remain if we are to
develop a comprehensive understanding about what hap-
pens to people once they are diagnosed with hepatitis C.
The findings summarized here contribute to the know-
ledge base and could inform the continuing development,
and revision, of national strategies aimed at reducing
the harms associated with hepatitis C around the world.
That the findings are synthesized from a wide range of
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potentially enhance their relevance to strategy develop-
ment and health service planning into the future. Yet
the picture still remains fragmented and incomplete.
The sometimes substantial impact of hepatitis C (and its
management) on QoL has been frequently investigated,
but only relatively short term follow up of changes in
QoL during the course of treatment has been reported.
Over the longer term people may experience fluctua-
tions in disease activity, modification of alcohol or other
drug use or changing social circumstances and it is likely
that these dynamic forces would influence QoL in a
manner that cannot be explored using traditional cross-
sectional approaches.
Planning for effective health and community service
provision for the growing number of people affected by
hepatitis C requires a good understanding of potential
trajectories, and the physiological and psychosocial
forces underlying them, from hepatitis C diagnosis into
the future. As people adapt to their diagnoses (as
described in the social research), what proportion go on
to find hepatitis has little or no impact on their lives,
and what proportion find hepatitis C exerts a significant
impact? At which points along their trajectory do people
engage with hepatitis C treatment or community sup-
port services, and do those services meet their expecta-
tions and needs? Do people reporting discrimination at
work or in the health system continue to have negative
experiences? Is it possible to map improvements in the
level of discrimination reported with increasing aware-
ness of hepatitis C in the broader population? How does
health status change over time, and how is health status
linked with changes in lifestyle factors (drinking, smok-
ing, other drug use) or with the social support people re-
ceive, or discrimination they perceive, at different points
in time. The research identifies a number of factors that
contribute to low uptake of antiviral treatment for hepa-
titis C. Decisions about treatment may be mediated by a
range of health and social factors that may vary over
time. It will become important to know how to over-
come identified barriers and effectively target informa-
tion as new treatments [75] and new management
strategies become available.
This study used a systematic approach to the search
strategy but may have been limited by incomplete re-
trieval of potentially relevant studies. Resource and time
restrictions limited the search to English Language pub-
lications and did not allow for a search of unpublished
data. It is possible that some ongoing studies of the
health and social impacts of hepatitis infection were not
identified. While our search of non-intervention studies
may have lessened the potential for publication bias,
there remains the possibility that our assessment of the
combined data may have overestimated the health andsocial impacts of hepatitis C. To minimize these poten-
tial source of bias, we searched three major data bases
using an inclusive search strategy, and all potentially eli-
gible studies were retrieved in full.Conclusion
This narrative review has provided a useful update on
many aspects of living with hepatitis C infection but has
also highlighted a number of important research gaps
that may have implications for hepatitis C strategy devel-
opment and implementation around the world. Many of
these gaps appear to be due to a methodological and
content gulf existing between the biomedical and social
research literature. Typically, cohort designs have been
used primarily in investigations of clinical or health out-
come – with exploration of social parameters primarily
focused on identifying their effect on outcome. In
broader social research, complex psychosocial phenom-
ena are more comprehensively explored, but temporal
change is often not a critical factor. Bridging the re-
search gaps will ultimately require a combined approach,
both content and methodology, to study the health and
social impacts of hepatitis C along the life course.Additional file
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